UPDATE on angiotensin II receptor blocker (ARB) recalls – FDA posts laboratory test results showing NDEA levels in recalled valsartan products as well as an assessment of the cancer risk from NDEA in valsartan: https://go.usa.gov/xm9MR .




Source